TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF THE U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET 12
1.4 CURRENCY AND PRICING 14
1.5 LIMITATIONS 14
1.6 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
2.6 MULTIVARIATE MODELLING 22
2.7 PRODUCT SEGMENT LIFELINE CURVE 22
2.8 MARKET END USER COVERAGE GRID 23
2.9 DBMR MARKET POSITION GRID 24
2.10 VENDOR SHARE ANALYSIS 26
2.11 SECONDARY SOURCES 27
2.12 ASSUMPTIONS 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 31
4.1 PESTEL ANALYSIS 32
4.2 PORTERS FIVE FORCES 33
5 INDUSTRY INSIGHTS 34
5.1 DEMOGRAPHIC TRENDS 34
5.2 KEY PRICING STRATEGIES 35
5.3 KEY PATIENT ENROLLMENT STRATEGIES 35
6 REIMBURSEMENT SCENARIO FOR REMOTE PATIENT MONITORING 37
7 REGULATORY FRAMEWORK 38
8 MARKET OVERVIEW 39
8.1 DRIVERS 41
8.1.1 RISING TECHNOLOGICAL ADVANCEMENTS 41
8.1.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML) 41
8.1.3 GROWING DEMAND FOR HOME HEALTHCARE 42
8.1.4 INCREASING PREVALENCE OF MUSCULOSKELETAL DISORDERS 42
8.2 RESTRAINTS 43
8.2.1 DATA SECURITY AND PRIVACY CONCERNS 43
8.2.2 HIGH COST ASSOCIATED WITH ELECTRONIC HEALTH RECORD (EHR) SERVICE 43
8.3 OPPORTUNITIES 44
8.3.1 GROWING EXPANSION OF TELEHEALTH IN THE U.S. 44
8.3.2 IMPROVED PATIENT OUTCOMES AND SELF-MANAGEMENT 44
8.3.3 RISING HEALTHCARE EXPENDITURE 45
8.4 CHALLENGES 45
8.4.1 SOFTWARE INCOMPATIBILITY ISSUES DUE TO VARYING DATA STANDARDS 45
8.4.2 REGULATORY AND LEGAL CHALLENGES 46
9 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY PRODUCT 47
9.1 OVERVIEW 48
9.2 SOLUTIONS SOFTWARE 51
9.3 SERVICES 51
9.4 HARDWARE 52
10 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY DEPLOYMENT MODE 53
10.1 OVERVIEW 54
10.2 CLOUD BASED 57
10.3 ON PREMISES 57
11 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY MODE OF ACCESS 58
11.1 OVERVIEW 59
11.2 MOBILE BASED 62
11.2.1 ANDROID 62
11.2.2 IOS 62
11.3 WEB BASED 63
12 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY CODES 64
12.1 OVERVIEW 65
12.2 98975 68
12.3 98976 68
12.4 98977 68
12.5 98980 69
12.6 98981 69
13 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY TYPE 70
13.1 OVERVIEW 71
13.2 CONTINUOUS MONITORING 74
13.3 PROACTIVE MONITORING 74
13.4 INTERMITTENT MONITORING 75
14 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY APPLICATION 76
14.1 OVERVIEW 77
14.2 NON PHYSIOLOGICAL DATA 80
14.3 THERAPEUTIC DATA 80
14.3.1 THERAPY ADHERENCE 81
14.3.2 THERAPY RESPONSE 81
15 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY PURCHASE MODE 82
15.1 OVERVIEW 83
15.2 GROUP PURCHASE 86
15.2.1 SOLUTIONS SOFTWARE 86
15.2.2 SERVICES 86
15.2.3 HARDWARE 86
15.3 INDIVIDUAL 87
15.3.1 SOLUTIONS SOFTWARE 87
15.3.2 SERVICES 87
15.3.3 HARDWARE 87
16 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY END USERS 88
16.1 OVERVIEW 89
16.2 PROVIDERS 92
16.2.1 HOME HEALTH 92
16.2.2 HOSPITALS 92
16.2.3 CLINICS 93
16.2.4 OTHERS 93
16.3 PAYERS 93
16.3.1 PRIVATE 93
16.3.2 PUBLIC 94
16.4 PATIENT 94
17 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET, BY DISTRIBUTION CHANNEL 95
17.1 OVERVIEW 96
17.2 DIRECT SALES 99
17.3 INDIRECT SALES 99
18 U.S. REMOTE THERAPEUTIC MONITORING (MSK) MARKET: COMPANY LANDSCAPE 100
18.1 COMPANY SHARE ANALYSIS: U.S. 100
19 COMPANY PROFILE 101
19.1 ZIMMER BIOMET. 101
19.1.1 COMPANY SNAPSHOT 101
19.1.2 REVENUE ANALYSIS 101
19.1.3 PRODUCT PORTFOLIO 102
19.1.4 RECENT DEVELOPMENT 102
19.2 OMADA HEALTH INC. 103
19.2.1 COMPANY SNAPSHOT 103
19.2.2 PRODUCT PORTFOLIO 103
19.2.3 RECENT DEVELOPMENTS 103
19.3 HEALTHVIEWX. 104
19.3.1 COMPANY SNAPSHOT 104
19.3.2 PRODUCT PORTFOLIO 104
19.3.3 RECENT DEVELOPMENT 104
19.4 PROPELLER HEALTH. 105
19.4.1 COMPANY SNAPSHOT 105
19.4.2 PRODUCT PORTFOLIO 105
19.4.3 RECENT DEVELOPMENT 105
19.5 LIMBER HEALTH, INC. 106
19.5.1 COMPANY SNAPSHOT 106
19.5.2 PRODUCT PORTFOLIO 106
19.5.3 RECENT DEVELOPMENTS 106
19.6 CENSON HEALTH 107
19.6.1 COMPANY SNAPSHOT 107
19.6.2 PRODUCT PORTFOLIO 107
19.6.3 RECENT DEVELOPMENTS 107
19.7 CIPHER SKIN INC. 108
19.7.1 COMPANY SNAPSHOT 108
19.7.2 PRODUCT PORTFOLIO 108
19.7.3 RECENT DEVELOPMENT 108
19.8 EXER LABS, INC 109
19.8.1 COMPANY SNAPSHOT 109
19.8.2 PRODUCT PORTFOLIO 109
19.8.3 RECENT DEVELOPMENT 109
19.9 HEALTHARC 110
19.9.1 COMPANY SNAPSHOT 110
19.9.2 PRODUCT PORTFOLIO 110
19.9.3 RECENT DEVELOPMENTS 110
19.10 INTELLIH INC. 111
19.10.1 COMPANY SNAPSHOT 111
19.10.2 PRODUCT PORTFOLIO 111
19.10.3 RECENT DEVELOPMENT 111
19.11 MEDISTICS LLC. 112
19.11.1 COMPANY SNAPSHOT 112
19.11.2 PRODUCT PORTFOLIO 112
19.11.3 RECENT DEVELOPMENT 112
19.12 MEDSIEN, INC. 113
19.12.1 COMPANY SNAPSHOT 113
19.12.2 PRODUCT PORTFOLIO 113
19.12.3 RECENT DEVELOPMENT 113
19.13 MURATA VIOS. 114
19.13.1 COMPANY SNAPSHOT 114
19.13.2 PRODUCT PORTFOLIO 114
19.13.3 RECENT DEVELOPMENT 114
19.14 OWLYTICS HEALTHCARE. 115
19.14.1 COMPANY SNAPSHOT 115
19.14.2 PRODUCT PORTFOLIO 115
19.14.3 RECENT DEVELOPMENTS 115
20 QUESTIONNAIRE 116
21 RELATED REPORTS 120

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.